OTC Markets OTCPK - Delayed Quote USD

Cannabis Bioscience International Holdings, Inc. (CBIH)

0.0006

-0.0001

(-14.29%)

At close: 9:31:12 AM EDT

Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 3 months ago

XBP

XBPEW

SKYH
Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification

HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CBIH is proud to announce that Brian Cuban, Esq., a distinguished attorney, best-selling author, mental health advocate, and esteemed member of our Advisory Board, has officially joined the Reclassification Team. Mr. Cuban will play a crucial role in representing CBIH at the upcoming DEA hearings on marijuana rescheduling. Brian Cuban, the younger brother of entrepreneur Mark Cuban, brings a unique combination of personal recovery experience and profess

GlobeNewswire 3 months ago

CBIH
-14.29%
Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products

HOUSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry. Stephen Gould, a company with a remarkable presence in over 40 locations across six countries, brings an

GlobeNewswire 3 months ago

CBIH
-14.29%
CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing

HOUSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (CBIH) continues its unwavering advocacy for cannabis as a legitimate medicine by formally petitioning to have Ms. Alexis Bortell, long-time cannabis advocate and patient, to serve as a witness in the upcoming DEA hearing on marijuana rescheduling. Alexis Bortell has been a leading voice in the fight for medical cannabis access since being diagnosed with intractable epilepsy at the age of seven. After enduring

GlobeNewswire 3 months ago

CBIH
-14.29%
A Letter from the Desk of CBIH

HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings Dear Community, On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege a

GlobeNewswire 4 months ago

CBIH
-14.29%
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 4 months ago

UCAR

OPWEF

BIXT
CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing

HOUSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) proudly announces its active participation in today’s DEA meaningful hearing on cannabis reclassification. Representing CBIH at this critical event in Arlington, Virginia, is Dante Picazo, the company’s esteemed Director and CEO, bringing years of expertise and leadership in the medical cannabis industry to Docket No. 1362, Hearing Docket No. 24-44. Mr. Picazo has presented a comprehensive 78-pa

GlobeNewswire 4 months ago

CBIH
-14.29%
CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip

HOUSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to set a standard in innovation with unparalleled momentum in intellectual property development. The company proudly stands with a remarkable portfolio of 13 unconventional patents. In addition, our Research and Development team is redefining the possibilities of cannabinoid-based biotechnologies and at the heart of these innovations lies the Rejuvenescence Chip, a pioneering advanceme

GlobeNewswire 4 months ago

CBIH
-14.29%
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions

HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical cannabinoid products. These initiatives are driven by CBIH's commitment to enhancing quality of life for individuals facing chronic, degenerative, and life-threatening illnesses. Moreover, the company aims to lead the future of medicine by developing innovative solutions such as mRNA

GlobeNewswire 4 months ago

CBIH
-14.29%
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44

HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of the few U.S. bioscience cannabis companies invited to participate in the DEA hearings on the rescheduling of marijuana. Represented by CEO, Mr. Dante Picazo, CBIH will present clinical trial data showcasing the therapeutic benefits and potential of Cannabis sativa L., emphasizing the company’s commitm

GlobeNewswire 5 months ago

CBIH
-14.29%
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy

Houston, Texas--(Newsfile Corp. - November 4, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to announce the appointment of Mr. Charles Tamburello as a new member of the board of directors. His extensive experience in the public markets, which spans nearly three decades, will play a crucial role in driving the company's mergers and acquisitions (M&A) strategy forward.Mr. Tamburello has been instrumental in the success of hundreds of public and private ...

Newsfile 5 months ago

CBIH
-14.29%
CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings

Houston, Texas--(Newsfile Corp. - October 28, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) trading on the OTC Markets under the ticker symbol CBIH has reached a major milestone in expanding its patent portfolio, filing six utility non-provisional applications for cannabinoid-based therapies that address underserved medical conditions. These patents cover therapeutic innovations for conditions such as pancreatic cancer (No. 18/905,128), breast cancer (No. 18/918,386), herpe

Newsfile 5 months ago

CBIH
-14.29%
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications

HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS:CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range. Preparations are underway for the production and distribution of our products, and continue to foster revenue expansion, which could only be achieved through the practical application o

GlobeNewswire 8 months ago

CBIH
-14.29%
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine

A letter from our desk Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications.From our desks - Rosangel Andrades and Jennifer Salguero.In the realm of medicine, patent

Newsfile 9 months ago

CBIH
-14.29%
CBIH Charts Path to Future Leadership in Cannabis Medicine

A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications. From our desks - Rosangel Andrades and Jennifer Salguero. In the realm of medicine, patent requir

GlobeNewswire 9 months ago

CBIH
-14.29%
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers

HOUSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration. Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic cancers. Th

GlobeNewswire 9 months ago

CBIH
-14.29%
CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments

Houston, Texas--(Newsfile Corp. - July 1, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration. Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic can

Newsfile 9 months ago

CBIH
-14.29%
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change

HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to introduce the groundbreaking strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands. As CBIH prepares for the manufacturing and distribution

GlobeNewswire 9 months ago

CBIH
-14.29%
CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader

Houston, Texas--(Newsfile Corp. - June 24, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to introduce the groundbreaking strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands.As CBIH prepares for the manufacturing and distr

Newsfile 9 months ago

CBIH
-14.29%
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation

HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation. This achievement is a testament of the paradigm shift which will allow patients and the medical industry to consider cannabinoids as the first option, not a last resource. Our significant valuation is the outcome of our unwavering dedication to growth and our persistent commit

GlobeNewswire 9 months ago

CBIH
-14.29%

Performance Overview

Return	CBIH	S&P 500 (^GSPC)
YTD	+20.00%	-10.18%
1-Year	-6.25%	+5.19%
3-Year	+33.33%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cannabis Bioscience International Holdings, Inc. (CBIH)

Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

Brian Cuban to Represent CBIH in DEA Hearings on Marijuana Reclassification

Cannabis Bioscience International Holdings (CBIH) Announces Partnership with Stephen Gould for Manufacturing and Distribution of Medical Products

CBIH Files Petition to Include Alexis Bortell as Witness in DEA Rescheduling Hearing

A Letter from the Desk of CBIH

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

CBIH Advocates for Cannabis Policy Reform at DEA Reclassification Hearing

CBIH Unveils the Future of Wellness with Revolutionary Anti-Aging Chip

CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions

Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44

CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy

CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings

CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications

CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine

CBIH Charts Path to Future Leadership in Cannabis Medicine

CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers

CBIH Submits Groundbreaking Cannabis Patents for Breast and Pancreatic Cancer Treatments

CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change

CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader

Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation

Performance Overview